Author

Jennifer H. Martin

Professor of Medicine and Clinical Pharmacology - Cited by 10,661 - clinical pharmacology - internal medicine

Biography

Jennifer H. Martin is a researcher. Jennifer H. Martin works as a professor in the Department of Internal Medicine, Princess Alexandra Hospital, Woolloongabba, Brisbane, Australia. her areaof research include:-History; Insulin; Recombinant; Methods of delivery
Title
Cited by
Year
“LONG COVID”—A hypothesis for understanding the biological basis and pharmacological treatment strategy
B Jarrott, R Head, KG Pringle, ER Lumbers, JH MartinPharmacology Research & Perspectives 10 (1), e00911, 2022202
65
2022
Systems analysis shows that thermodynamic physiological and pharmacological fundamentals drive COVID‐19 and response to treatment
RJ Head, ER Lumbers, B Jarrott, F Tretter, G Smith, KG Pringle, S Islam, ...Pharmacology Research & Perspectives 10 (1), e00922, 2022202
23
2022
Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy
WA Clarke, E Chatelut, AK Fotoohi, RA Larson, JH Martin, ...European Journal of Cancer 157, 428-440, 2021202
16
2021
Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target
S Islam, S Wang, N Bowden, J Martin, R HeadBritish Journal of Clinical Pharmacology 88 (1), 64-74, 2022202
16
2022
Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial
EN Hurley, CJ Ellaway, AM Johnson, L Truong, R Gordon, P Galettis, ...Epilepsia 63 (), 136-14, 2022202
7
2022
Measurement of 5-fluorouracil, capecitabine and its metabolite concentrations in blood using volumetric absorptive microsampling technology and LC-MS/MS
M Radovanovic, JJ Schneider, M Shafiei, JH Martin, P GalettisJournal of Chromatography B 1188, 123075, 2022202
6
2022
A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing
S Glewis, M Alexander, MNH Khabib, A Brennan, S Lazarakis, J Martin, ...British Journal of Cancer 127 (1), 12-13, 2022202
6
2022
NSW Cannabis Medicines Advisory Service preliminary survey results: enquirer perceptions and patient outcomes
M Graham, S Bird, Z Howard, M Dobson, K Palazzi, CJ Lucas, ...Internal medicine journal 2 (2), 228-237, 2022202
5
2022
A practical treatment for COVID‐19 and the next pandemic
J Bhattacharya, R Booy, A Casadevall, CD Cruz, DS Fedson, JGN Garcia, ...Pharmacology Research & Perspectives 10 (4), 2022202
5
2022
Pharmacokinetics, Safety, and Tolerability of a Medicinal Cannabis Formulation in Patients with Chronic Non-cancer Pain on Long-Term High Dose Opioid Analgesia: A Pilot Study
Y Bonomo, A Norman, L Collins, H O’Neill, P Galettis, J Trinca, N Strauss, ...Pain and Therapy 11 (1), 171-189, 2022202
5
2022
Obesity and COVID-19: renin–angiotensin as a mediator of morbidity and mortality
JH Martin, RE HeadBritish Journal of Nutrition 127 (9), 139-10, 2022202
4
2022
Combined In Silico and In Vitro Evidence Supporting an Aurora A Kinase Inhibitory Role of the Anti-Viral Drug Rilpivirine and an Anti-Proliferative Influence on …
S Islam, T Teo, M Kumarasiri, M Slater, JH Martin, S Wang, R HeadPharmaceuticals 15 (10), 1186, 2022202
3
2022
Aboriginal and Torres Strait Islander patients’ cancer care pathways in Queensland: Insights from health professionals
A de Witt, V Matthews, R Bailie, PC Valery, J Adams, G Garvey, JH Martin, ...Health Promotion Journal of Australia 33 (3), 701-710, 0
2
2022
Complementary and alternative therapies in the palliative setting
JH Martin, J PatelInternal Medicine Journal 5 (10), 1677-1684, 0
2
2022
Cannabidiol drug interaction considerations for prescribers and pharmacists
M Graham, JH Martin, CJ Lucas, B Murnion, J SchneiderExpert Review of Clinical Pharmacology 15 (1), 1383-1397, 0
2
2022
Medicinal Cannabis Guidance and Resources for Health Professionals to Inform Clinical Decision Making
M Graham, E Renaud, CJ Lucas, J Schneider, JH MartinClinical Therapeutics 45 (6), 527-534, 2023202
1
2023
Critical insights to COVID‐19 disease and potential treatments using a systems analysis approach that integrates physiology, pharmacology, and clinical pharmacology
Critical insights to COVID‐9 disease and potential treatments using a systems analysis approach that integrates physiology, pharmacology, and clinical pharmacologyJH Martin, RJ HeadPharmacology Research & Perspectives 0 (), 2022202
1
2022
Patient‐oriented medication education intervention has long‐term benefits for people with decompensated cirrhosis
KL Hayward, V Bansal, PC Valery, KM Irvine, PL Wright, CJ Tallis, ...Hepatology Communications 6 (), 328-3282, 2022202
1
2022
Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolites
Z Liu, JH Martin, W Liauw, SA McLachlan, E Link, A Matera, M Thompson, ...European Journal of Clinical Pharmacology 78, 53-64, 2022202
1
2022
Did our pharmacological strategy for COVID‐19 fail?
Did our pharmacological strategy for COVID‐9 fail?JH Martin, M Baddeley, R HeadPharmacology Research & Perspectives 9 (6), 20220
1
2021

Referred From: https://scholar.google.com/citations?user=y67JQroAAAAJ&hl=en

Cited by
Citations 10661
h-index 49
i10-index 152
Recommended Journals
Open Access Journals